Atossa Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ATOS | LONA | TPST | ALGS | MREO | DTC.CN | |
|---|---|---|---|---|---|---|
| Market cap | 21.16M | 43.01M | 9.26M | 31.35M | 48.40M | 25.50M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.6 | — | -0.4 | -1.0 | -13.1 | — |
| Price/book | 0.8 | 1.3 | -6.8 | 1.0 | 1.7 | 7.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −81.29% | +13.84% | −95.29% | −35.20% | −82.78% | −63.04% |
| Today | −9.01% | −4.30% | −1.13% | +5.68% | +4.16% | −1.47% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ATOS news ›News from Atossa Therapeutics Inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.
news News from Atossa Therapeutics Inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Oct 19, 2026,…
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
Sep 29, 2026, 08:00 ET Shareholders would receive one CVR for each ATOS share held as of the record date or issued thereafter CVRs would entitle holders to 25% of net proceeds from monetization of Atossa's first qualifying priority review…
Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value
Oct 09, 2026, 08:00 ET Board declares one stapled CVR for each share of Atossa common stock outstanding as of October 19, 2026 record date or issued thereafter CVRs entitle holders to 25% of net proceeds from monetization of Atossa's first…
Germantown’s Seraxis and Sernova Close $11.2 Million Financing Ahead of Merger to Form BetaNova Biotherapeutics
Germantown's Seraxis and Sernova Close $11.2 Million Financing Ahead of Merger to Form BetaNova Biotherapeutics BioBuzz Germantown’s Seraxis and Sernova Close $11.2 Million Financing Ahead of Merger to Form BetaNova Biotherapeutics Sernova…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- prnewswire.com3
- biobuzz.io1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 4 articles, not a forecast.